Mesalazine Faes (Mesalazine)

Mesalazine Faes belongs to the aminosalicylate class and is employed in the management of inflammatory bowel disease.

• Ulcerative colitis: induces remission and reduces mucosal inflammation.
• Crohn's disease (colonic involvement): helps maintain remission and control intestinal inflammation.
• Maintenance therapy for IBD: prolongs periods without flare and supports long‑term disease control.

• Mesalazine acts locally in the intestinal lumen, where it inhibits cyclooxygenase and lipoxygenase pathways, decreasing synthesis of prostaglandins and leukotrienes. This reduction in inflammatory mediators leads to diminished mucosal inflammation and promotes healing of the intestinal lining in affected segments.

Mesalazine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Nausea or abdominal discomfort: transient gastrointestinal upset.
• Diarrhea: occasional loose stools.
• Rash or mild skin irritation: limited to the area of exposure.

Serious or Rare Side Effects

• Severe hypersensitivity reactions: including anaphylaxis or Stevens‑Johnson syndrome.
• Hepatotoxicity: elevated liver enzymes or hepatitis.
• Nephrotoxicity: interstitial nephritis or reduced renal function.

Before initiating therapy, consider the following safety measures.

• Renal function monitoring: assess baseline creatinine and periodic checks during treatment.
• Hepatic assessment: evaluate liver enzymes before and during therapy.
• Blood counts: monitor for leukopenia or anemia if long‑term use is planned.
• Pregnancy and lactation: discuss potential risks with a healthcare professional before use.
• Drug interactions: review concomitant medications for possible interactions.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Mesalazine can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

• Azathioprine or 6‑mercaptopurine: may increase risk of bone‑marrow suppression.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can raise the likelihood of renal impairment.

Moderate Interactions (Monitor Closely)

• Anticoagulants (e.g., warfarin): may enhance anticoagulant effect.
• Oral corticosteroids: may augment gastrointestinal side effects.
• Antibiotics such as metronidazole: potential for additive neurotoxicity.